PIK3CA-Mutated Cancers clinical trials at UCSD

1 research study open to eligible people

Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
open to eligible people ages 18 years and up
The purpose of the study is to assess the safety and efficacy of inavolisib as a single-agent and in combination with atezolizumab in participants with phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)-mutated cancers, including previously treated head and neck squamous cell carcinoma (HNSCC).
La Jolla, California and other locations

Last updated: October 1, 2024

Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers